

Table S1. Regression coefficients and 95% confidence intervals for the relationship between age groups and dATP and dCTP, using the older (≥ 60 years) group as the reference, from linear models adjusting for clinical and demographic covariates.

Parameter		dATP		dCTP	
		Effect (95% confidence interval)	p-value	Effect (95% confidence interval)	p-value
Intercept		2.66 (0.62,4.70)	0.011	2.20 (0.73,3.68)	0.0035
Age Group	≤ 45 years	-0.21 (-0.48,0.062)	0.13	-0.051 (-0.25,0.14)	0.61
	≥ 60 years (reference)				
Current Smoking Status	Current Smoker	0.0059 (-0.18,0.19)	0.95	-0.039 (-0.17,0.095)	0.57
	Current Nonsmoker (reference)				
Race	Black	-0.20 (-0.51,0.11)	0.20	0.12 (-0.10,0.34)	0.29
	Other	-0.14 (-0.49,0.20)	0.41	0.080 (-0.17,0.33)	0.53
	White (reference)				
ART^a Background	Other	0.015 (-0.35,0.38)	0.94	0.075 (-0.19,0.34)	0.58
	Integrase Inhibitor	-0.0059 (-0.22,0.21)	0.96	-0.028 (-0.18,0.13)	0.73
	Atazanavir OR Lopinavir	0.019 (-0.24,0.28)	0.89	0.11 (-0.075,0.30)	0.24
	Darunavir	0.23 (-0.074,0.53)	0.14	0.12 (-0.10,0.34)	0.30
	Efavirenz (reference)				
log₁₀(eGFR)^b		0.074 (-0.89,1.04)	0.88	0.092 (-0.61,0.79)	0.80
Any Hypertension	Yes	-0.011 (-0.21,0.18)	0.91	-0.053 (-0.20,0.089)	0.46
	No (reference)				
Any Diabetes	Yes	0.11 (-0.13,0.36)	0.36	0.19 (0.011,0.37)	0.038
	No (reference)				
log₁₀(APRI)^c		-0.21 (-0.51,0.094)	0.18	-0.32 (-0.54,-0.098)	0.0046
log₁₀(BMI)^d		-0.095 (-0.83,0.65)	0.80	0.016 (-0.52,0.55)	0.95
Scale		0.50 (0.44,0.56)		0.36 (0.32,0.40)	

a ART: antiretroviral therapy

b eGFR: estimated glomerular filtration rate, as calculated by the CKD-EPI equation

c APRI: AST-to-platelet ratio index

d BMI: body mass index; reported in 59 women in the older group and 83 in the younger group; 3/59 and 1/83 in the older and younger groups, respectively, used imputed values from the WIHS visit immediately before or after the visit of interest

Table S2. Regression coefficients and 95% confidence intervals for the relationship between age groups and emtricitabine triphosphate (FTCtp) and tenofovir diphosphate (TFVdp), using the older (≥ 60 years) group as the reference, from linear models adjusting for clinical and demographic covariates.

Parameter		FTCtp		TFVdp	
		Effect (95% confidence interval)	p-value	Effect (95% confidence interval)	p-value
Intercept		3.91 (1.92,5.89)	0.00012	4.88 (3.24,6.52)	<0.0001
Age Group	≤ 45 years				
	≥ 60 years (reference)	-0.067 (-0.33,0.20)	0.62	-0.17 (-0.38,0.049)	0.13
Current Smoking Status	Current Smoker				
	Current Nonsmoker (reference)	0.054 (-0.13,0.23)	0.55	-0.0083 (-0.16,0.14)	0.91
Race	Black	-0.28 (-0.58,0.022)	0.069	-0.026 (-0.27,0.22)	0.83
	Other	-0.040 (-0.38,0.30)	0.82	-0.063 (-0.34,0.22)	0.66
	White (reference)				
ART^a Background	Other	-0.17 (-0.52,0.19)	0.35	0.10 (-0.19,0.40)	0.50
	Integrase Inhibitor	-0.12 (-0.33,0.086)	0.25	0.049 (-0.12,0.22)	0.58
	Atazanavir OR Lopinavir	0.074 (-0.18,0.32)	0.56	0.048 (-0.16,0.25)	0.65
	Darunavir	0.13 (-0.17,0.42)	0.40	0.14 (-0.099,0.39)	0.25
	Efavirenz (reference)				
log₁₀(EGFR)^b		0.10 (-0.84,1.04)	0.83	-0.82 (-1.60,-0.049)	0.037
Any Hypertension	Yes				
	No (reference)	-0.023 (-0.21,0.17)	0.81	-0.11 (-0.27,0.046)	0.17
Any Diabetes	Yes				
	No (reference)	0.25 (0.0045,0.49)	0.046	0.19 (-0.012,0.39)	0.066
log₁₀(APRI)^c		-0.33 (-0.62,-0.033)	0.029	-0.24 (-0.49,0.00020)	0.050
log₁₀((BMI)^d Scale		-0.17 (-0.89,0.55)	0.65	-0.80 (-1.39,-0.20)	0.0085
		0.48 (0.43,0.54)		0.40 (0.35,0.45)	

a ART: antiretroviral therapy

b eGFR: estimated glomerular filtration rate, as calculated by the CKD-EPI equation

c APRI: AST-to-platelet ratio index

d BMI: body mass index; reported in 59 women in the older group and 83 in the younger group; 3/59 and 1/83 in the older and younger groups, respectively, used imputed values from the WIHS visit immediately before or after the visit of interest

Table S3. Regression coefficients and 95% confidence intervals for the relationship between age groups and the tenofovir diphosphate (TFVdp):dATP ratio and the emtricitabine triphosphate (FTCtp):dCTP ratio, using the older (≥ 60 years) group as the reference, from linear models adjusting for clinical and demographic covariates.

Parameter		TFVdp:dATP ratio		FTCtp:dCTP ratio	
		Effect (95% confidence interval)	p-value	Effect (95% confidence interval)	p-value
Intercept		2.32 (0.83,3.82)	0.0024	1.70 (-0.24,3.64)	0.085
Age Group	≤ 45 years				
	≥ 60 years (reference)	0.037 (-0.16,0.24)	0.72	-0.016 (-0.27,0.24)	0.90
Current Smoking Status	Current Smoker				
	Current Nonsmoker (reference)	-0.0093 (-0.15,0.13)	0.89	0.093 (-0.082,0.27)	0.30
Race	Black	0.16 (-0.065,0.38)	0.16	-0.40 (-0.69,-0.11)	0.0075
	Other	0.064 (-0.19,0.32)	0.62	-0.12 (-0.45,0.21)	0.48
	White (reference)				
ART^a Background	Other	0.10 (-0.17,0.37)	0.46	-0.24 (-0.59,0.10)	0.17
	Integrase Inhibitor	0.059 (-0.10,0.22)	0.47	-0.097 (-0.30,0.11)	0.35
	Atazanavir OR Lopinavir	0.044 (-0.15,0.23)	0.65	-0.037 (-0.28,0.21)	0.77
	Darunavir	-0.069 (-0.29,0.15)	0.54	0.0092 (-0.28,0.30)	0.95
	Efavirenz (reference)				
log₁₀(EGFR)^b		-0.95 (-1.65,-0.24)	0.0085	0.0090 (-0.91,0.92)	0.98
Any Hypertension	Yes				
	No (reference)	-0.096 (-0.24,0.049)	0.20	0.031 (-0.16,0.22)	0.74
Any Diabetes	Yes				
	No (reference)	0.089 (-0.092,0.27)	0.33	0.055 (-0.18,0.29)	0.65
log₁₀(APRI)^c		-0.072 (-0.30,0.15)	0.53	-0.010 (-0.30,0.28)	0.94
log₁₀(BMI)^d		-0.73 (-1.27,-0.18)	0.0086	-0.18 (-0.89,0.52)	0.61
Scale		0.36 (0.32,0.41)		0.47 (0.42,0.53)	

a ART: antiretroviral therapy

b eGFR: estimated glomerular filtration rate, as calculated by the CKD-EPI equation

c APRI: AST-to-platelet ratio index

d BMI: body mass index; reported in 59 women in the older group and 83 in the younger group; 3/59 and 1/83 in the older and younger groups, respectively, used imputed values from the WIHS visit immediately before or after the visit of interest

Table S4. Regression coefficients and 95% confidence intervals for the relationship between age groups and IL-6 and sCD163 concentrations, using the older (≥ 60 years) group as the reference, from linear models adjusting for clinical and demographic covariates.

Parameter		IL-6		sCD163	
		Effect (95% confidence interval)	p-value	Effect (95% confidence interval)	p-value
Intercept		0.79 (-2.61,4.19)	0.65	1.70 (0.84,2.57)	0.00011
Age Group	≤ 45 years				
	≥ 60 years (reference)	0.10 (-0.40,0.60)	0.69	-0.13 (-0.24,-0.016)	0.025
Current Smoking Status	Current Smoker				
	Current Nonsmoker (reference)	0.21 (-0.14,0.55)	0.25	0.020 (-0.058,0.098)	0.61
Race	Black	0.30 (-0.28,0.87)	0.32	0.022 (-0.11,0.15)	0.74
	Other	0.57 (-0.11,1.25)	0.10	0.16 (0.0097,0.30)	0.037
	White (reference)				
ART^a Background	Other	0.63 (-0.055,1.31)	0.071	0.11 (-0.044,0.27)	0.16
	Integrase Inhibitor	-0.020 (-0.43,0.39)	0.92	0.064 (-0.028,0.15)	0.17
	Atazanavir OR Lopinavir	0.52 (0.042,1.00)	0.033	0.0096 (-0.099,0.12)	0.86
	Darunavir	-0.087 (-0.66,0.48)	0.76	-0.13 (-0.26,-0.0020)	0.047
	Efavirenz (reference)				
log₁₀(EGFR)^b		-0.65 (-2.44,1.15)	0.48	0.42 (0.012,0.83)	0.044
Any Hypertension	Yes				
	No (reference)	0.089 (-0.28,0.46)	0.63	-0.035 (-0.12,0.048)	0.41
Any Diabetes	Yes				
	No (reference)	-0.066 (-0.54,0.41)	0.79	0.0039 (-0.10,0.11)	0.94
log₁₀(APRI)^c		-0.43 (-0.99,0.14)	0.14	0.19 (0.063,0.32)	0.0035
log₁₀(BMI)^d		NA	NA	0.39 (0.075,0.70)	0.015
BMI^e (categorical)	Underweight (<18.5)	-0.55 (-1.39,0.30)	0.21		
	Normal (18.5-24.9)	-1.02 (-1.49,-0.54)	<0.0001	NA	NA
	Overweight (25-29.9)	-0.48 (-0.94,-0.013)	0.044		

	Obese (30-34.9)	-0.034 (-0.48,0.42)	0.88		
	Extremely obese (>35) (reference)				
Scale		0.92 (0.81,1.04)		0.21 (0.19,0.24)	

a ART: antiretroviral therapy

b eGFR: estimated glomerular filtration rate, as calculated by the CKD-EPI equation

c APRI: AST-to-platelet ratio index

d BMI: body mass index, as a continuous variable for the sCD163 model; reported in 59 women in the older group and 83 in the younger group; 3/59 and 1/83 in the older and younger groups, respectively, used imputed values from the WIHS visit immediately before or after the visit of interest

e BMI: body mass index, as a categorical variable for the IL-6 model; reported in 59 women in the older group and 83 in the younger group; 3/59 and 1/83 in the older and younger groups, respectively, used imputed values from the WIHS visit immediately before or after the visit of interest

Table S5. Regression coefficients and 95% confidence intervals for the relationship between age groups and % senescent cells, using the older (≥ 60 years) group as the reference, from linear models adjusting for clinical and demographic covariates.

Parameter		% Senescent Cells (+1 on log scale)	
		Effect (95% confidence interval)	p-value
Intercept		0.11 (-1.24,1.47)	0.87
Age Group	≤ 45 years	-0.10 (-0.28,0.074)	0.25
	≥ 60 years (reference)		
Current Smoking Status	Current Smoker	0.058 (-0.064,0.18)	0.35
	Current Nonsmoker (reference)		
Race	Black	-0.14 (-0.33,0.062)	0.18
	Other	-0.045 (-0.27,0.18)	0.69
	White (reference)		
ART^a Background	Other	-0.083 (-0.31,0.15)	0.47
	Integrase Inhibitor	0.093 (-0.045,0.23)	0.19
	Atazanavir OR Lopinavir	0.059 (-0.11,0.23)	0.50
	Darunavir	0.10 (-0.10,0.31)	0.33
	Efavirenz (reference)		
log₁₀(EGFR)^b		0.10 (-0.52,0.73)	0.74
Any Hypertension	Yes	0.032 (-0.095,0.16)	0.63
	No (reference)		
Any Diabetes	Yes	-0.035 (-0.19,0.12)	0.67
	No (reference)		
log₁₀(APRI)^c		0.079 (-0.11,0.27)	0.42
log₁₀(BMI)^d		0.40 (-0.092,0.89)	0.11
Scale		0.31 (0.27,0.35)	

a ART: antiretroviral therapy

b eGFR: estimated glomerular filtration rate, as calculated by the CKD-EPI equation

c APRI: AST-to-platelet ratio index

d BMI: body mass index; reported in 59 women in the older group and 83 in the younger group; 3/59 and 1/83 in the older and younger groups, respectively, used imputed values from the WIHS visit immediately before or after the visit of interest